| 查看: 1656 | 回复: 2 | |||||||
liuchongyu铜虫 (小有名气)
|
[交流]
辉瑞中国招聘区域医学顾问
|
简历发送至：pfizerhr@sina.cn 职位名称：区域医学顾问/Regional Medical Advisor 工作地点：上海/Shanghai 职责Responsibilities Maximize the value of Pfizer products to Chinese patients and health care professional within Pfizer’s vision and mission. Develop KOLs management strategy and action plan. Establish the channel with China academic organization in the field to communicate Pfizer products medical information to key influencers and stakeholders. Implement medical programs and activities of inline products and pipeline in the fields. Provide professional medical training to commercial teams. 要求Qualifications •Technical Therapeutic area knowledge: familiar with the disease knowledge and clinical practice of the therapeutic area Language: Proficiency in oral and written English Good understanding about pharmaceutical business Computer: Good at Microsoft Office software Strong business acumen Cross functional leadership skill Strong communication and influencing skill •Managerial Sustain Focus on Performance Create an Inclusive Environment Encourage Open Discussion and Debate Manage Change Develop People Align Across Pfizer •Education Medical Background, Master Degree or above in the defined therapeutic area is preferred •Experience At least 2 years clinical practice experience in defined area with good medical knowledge Good understanding about pharmaceutical business, Medical affairs experience or clinical studies experience in multinational pharmaceutical companies is preferred Proficiency in English and good computer usage |
回复此楼» 猜你喜欢
售SCI一区T0P文章，我:8O.55.1.O.54,科目全,可伽急
已经有3人回复
-
售SCI一区T0P文章，我:8.O.55.1.O.5.4,科目全,可+急
已经有3人回复
-
售SCI一区T0P文章，我:8.O.55.1.O.5.4,科目全,可+急
已经有3人回复
-
售SCI一区T0P文章，我:8O.55.1.O.54,科目全,可伽急
已经有3人回复
-
售SCI一区T0P文章，我:8O.55.1.O.5.4,科目齐全,可+急
已经有5人回复
-
售SCI一区T0P文章，我:8.O55.1.O.54,科目全,可十急
已经有3人回复
-
售SCI一区文章，我:8O5.5.1.O5.4,科目全,可伽急
已经有5人回复
-
售SCI一区文章，我:8O5.5.1.O5.4,科目全,可伽急
已经有4人回复
-
售SCI一区文章，我:8.O.551.O.5.4,科目全,可伽急
已经有3人回复
-
售SCI一区文章，我:8.O.551.O.5.4,科目全,可伽急
已经有5人回复
2楼2012-09-25 21:42:02
3楼2012-09-25 21:58:12
